2 days ago
4
David Jagielski, CPA, The Motley Fool
Mon, May 18, 2026 astatine 11:20 AM CDT 5 min read
Although the banal marketplace whitethorn look blistery these days and mostly overvalued, determination are immoderate gems you tin find retired there, with galore stocks priced beneath $100. If you're a semipermanent investor, past 3 stocks you'll privation to see loading up connected close present are Pfizer (NYSE: PFE), Novo Nordisk (NYSE: NVO), and PDD Holdings (NASDAQ: PDD).
These stocks are incredibly cheap, and here's wherefore they could look similar steals successful a fewer years.
Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected a little-known company, called an "Indispensable Monopoly," providing the captious exertion Nvidia and Intel some need.
Pfizer
One banal that can't drawback overmuch of a interruption these days is Pfizer. Although it has been trading astatine a discount for years, investors inactive aren't anxious to bargain it. Currently, it's trading astatine astir $25, and this year, it's up astir 1%, which doesn't connection overmuch comfortableness to investors who person been hanging connected for 5 years -- their concern successful the institution remains down astir 37%.
The large hazard with Pfizer is slowing maturation and looming patent cliffs connected cardinal drugs. Those are sizeable concerns, but I besides judge they are a spot overblown. Facing cause expirations is an inevitable occupation successful the healthcare sector. The bully quality is that Pfizer has astatine slightest been making a sizeable effort successful expanding its pipeline and pursuing maturation opportunities, specified arsenic its acquisition of Metsera past year, which gave it a promising GLP-1 plus successful MET-097i.
Pfizer is inactive a large subordinate successful the healthcare industry, with its gross totaling $62.6 cardinal past year. And though that was down somewhat from the erstwhile year, with the institution making continued investments into its growth, I judge it's connected the close path. It whitethorn instrumentality immoderate time, but with the banal trading astatine conscionable 9 times aboriginal net (based connected expert forecasts), there's immoderate fantabulous borderline of information here. Plus, Pfizer's banal besides pays 6.8% successful dividends.
Novo Nordisk
Novo Nordisk is different healthcare institution that's successful a pugnacious spot. It has immoderate terrific GLP-1 drugs successful Wegovy and Ozempic that regulators person already approved, and which are generating a ton of gross for the business. But with rising competition, it's besides facing immoderate headwinds this twelvemonth owed to little prices. The company's adjusted income for the archetypal 3 months of the twelvemonth were down 4% (at changeless speech rates).
However, with its Wegovy pill successful its aboriginal stages and showing beardown request retired of the gate, there's crushed to beryllium optimistic that Novo Nordisk's maturation whitethorn look overmuch amended successful the future. And a higher-dose mentation of Wegovy has besides been showing encouraging aboriginal signs that it whitethorn assistance radical suffer arsenic overmuch arsenic 28% of their assemblage weight. That benignant of show could assistance it wrestle distant marketplace stock from rival Eli Lilly.
English (CA) · 
English (US) · 
Spanish (MX) ·